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TRAF2 Facilitates Vaccinia Virus Replication by Promoting Rapid
Virus Entry
Ismar R. Haga,a Tali Pechenick Jowers,a Samantha J. Grifﬁths,b Juergen Haas,b Philippa M. Bearda
The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, United Kingdoma; Division of Pathway Medicine and Centre of
Infectious Diseases, University of Edinburgh, Edinburgh, United Kingdomb
ABSTRACT
Tumor necrosis factor receptor (TNFR)-associated factor 2 (TRAF2) is a pivotal intracellular mediator of signaling pathways
downstream of TNFR1 and -2 with known pro- and antiviral effects. We investigated its role in the replication of the prototype
poxvirus vaccinia virus (VACV). Loss of TRAF2 expression, either through small interfering RNA treatment of HeLa cells or
through genetic knockout in murine embryonic fibroblasts (MEFs), led to significant reductions in VACV growth following low-
multiplicity infection. In single-cycle infections, there was delayed production of both early and late VACV proteins as well as
accelerated virus-induced alterations to cell morphology, indicating that TRAF2 influences early stages of virus replication. Con-
sistent with an early role, uncoating assays showed normal virus attachment but delayed virus entry in the absence of TRAF2.
Although alterations to c-Jun N-terminal kinase (JNK) signaling were apparent in VACV-infected TRAF2/MEFs, treatment of
wild-type cells with a JNK inhibitor did not affect virus entry. Instead, treatment with an inhibitor of endosomal acidification
greatly reduced virus entry into TRAF2/MEFs, suggesting that VACV is reliant on the endosomal route of entry in the absence
of TRAF2. Thus, TRAF2 is a proviral factor for VACV that plays a role in promoting efficient viral entry, most likely via the
plasmamembrane.
IMPORTANCE
Tumor necrosis factor receptor-associated factors (TRAFs) are key facilitators of intracellular signaling with roles in innate and
adaptive immunity and stress responses. We have discovered that TRAF2 is a proviral factor in vaccinia virus replication in both
HeLa cells andmouse embryonic fibroblasts and that its influence is exercised through promotion of efficient virus entry.
Tumor necrosis factor receptor (TNFR)-associated factors(TRAFs) are key facilitators of intracellular signaling with
roles in innate and adaptive immunity, stress responses, and bone
metabolism (1). There are seven members of the TRAF family,
TRAF1 to TRAF7, with all TRAFs except TRAF4 being involved in
signaling downstream of the TNFR superfamily. TRAF2mediates
signaling of multiple pathways downstream of TNFR1 and -2,
leading to the activation of both canonical and noncanonical
NF-B pathways (2), inhibition of apoptosis via interaction
with caspase 8 (3, 4), and activation of the mitogen-activated
protein kinases (MAPKs) p38 (5) and c-Jun N-terminal kinase
(JNK) (6, 7).
JNK is a stress-activated protein kinase (SAPK) that is activated
by cytokines, such as tumor necrosis factor alpha (TNF-), by
environmental stress, and also by intracellular stimuli, such as
endoplasmic reticulum stress (8). The JNK signaling cascade in-
cludes various members of the MAPK kinase kinase (MAP3K)
family which activate the MAPK kinases MKK4 and -7, leading to
phosphorylation and activation of JNK. JNK substrates include
not only nuclear transcription factors, such as AP-1 and c-Jun, but
also nonnuclear proteins, such as the E3 ligase Itch; themitochon-
drial antiapoptotic proteins Bcl2 and Bcl-xL; and regulators of cell
movement, such as paxillin and microtubule-associated proteins
MAP2 andMAP1B (8). These interactions allow the JNK pathway
to influence a wide range of cell processes, including apoptosis,
inflammation, protein degradation, cell cycle progression, and cy-
toskeletal regulation (9). Due to the multiple cellular functions
regulated by JNK, manipulation of this signaling pathway is a
strategy employed by a number of viruses, including poxviruses,
in order to regulate cellular gene expression (10–14).
Poxviruses belong to the Poxviridae, a family of large DNA
viruses that replicate entirely within the cytoplasm of the cell (15).
The best characterized member of the family is Vaccinia virus
(VACV), a member of the Orthopoxvirus genus, which also in-
cludes Cowpox virus, Ectromelia virus (the causative agent of
mousepox), Monkeypox virus, and Variola virus, the causative
agent of smallpox. VACV produces two forms of infectious prog-
eny known as intracellular mature virus (IMV) and extracellular
enveloped virus (EEV). IMVs consist of a core particle containing
the viral genome and a selection of host and viral proteins sur-
rounded by a single membrane. IMVs make up the majority of
infectious progeny, and most remain inside the infected cell until
cell lysis (16). However, a small proportion of IMVs are processed
further and transported to the cell surface for release as double-
enveloped EEV particles. EEVs represent only aminor proportion
of the progeny virus in tissue culture, but they are biologically
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important, as they mediate the dissemination of virus within the
infected host.
Once an EEV particle contacts an uninfected cell, it loses its
outer membrane by nonfusogenic disruption (17), allowing the
underlying IMV to enter the cell as a normal IMVwould. Initially,
the VACV IMV particle uses various host molecules, including
glycosaminoglycans, heparan sulfate, and chondroitin, to attach
to the cell surface (18–21). This is followed by internalization via
fusion either at the plasma membrane (22, 23) or in acidified
endosomes following macropinocytosis (24–26). The fusion of
viral and host membranes via either route utilizes a complex
membrane fusion apparatus made up of 11 to 12 viral proteins
(25). Entry of VACV into a cell is still incompletely understood,
with different strains of the virus utilizing different routes to enter
different cell types (25, 27–30).
Once inside the cell, VACV initiates complex and largely ill-
defined pathway manipulations to render the intracellular envi-
ronment optimal for virus replication. For example, it possesses
numerous mechanisms to evade the host immune response, with
the inhibition of NF-B activation being especially robust (31).
VACV manipulates MAPK pathways during replication (32, 33),
including stimulation of JNK in a sustained manner during the
infectious cycle (13). In addition, VACV rapidly remodels the cy-
toskeleton of the cell, producing a distinctive cytopathic effect
(CPE) characterized by cell rounding, loss of adhesion, and acti-
vation of cellmigrationwithin the first 2 to 3 h postinfection (p.i.),
followed by cell flattening, reattachment, and projection forma-
tion (34–38). These virally induced cytoskeletal changes rely at
least in part on inhibition of RhoA signaling pathways by the vi-
rally encoded F11 protein (39–41) and mirror alterations seen in
wound healing and tumor metastasis (36), making VACV-host
cell interactions relevant to a wide spectrum of biomedical re-
search.
In order to elucidate how VACV manipulates host cell path-
ways, we investigated the role of TRAF2, a key pathway regulator,
in VACV replication. We discovered that TRAF2 is a proviral fac-
tor in VACV replication in both HeLa cells andmouse embryonic
fibroblasts (MEFs) and that its influence is exercised through pro-
motion of efficient virus entry.
MATERIALS AND METHODS
Cells and viruses. Cells (African green monkey kidney epithelioid
[BS-C-1] cells, human cervix carcinoma epithelioid [HeLa] cells, andMEFs)
were grown in Dulbecco’s modified Eagle’s medium (DMEM; Life Tech-
nologies) containing 50 IU/ml penicillin, 50g/ml streptomycin (Sigma),
and 10% fetal bovine serum (FBS; Life Technologies). TRAF2/ and
TRAF2/MEFs (42) were sent by Søren R. Paludan (University of Aar-
hus, Aarhus, Denmark) with the permission of Tak W. Mak (Campbell
Family Institute for Breast Cancer Research, Canada). Cells were incu-
bated at 37°C in a 5% CO2 incubator. VACV strain Western Reserve
(VACV) and VACV A5L-EGFP, in which enhanced green fluorescent
protein (EGFP) is fused to the VACV core protein A5 (43), were kind gifts
from Geoffrey L. Smith (University of Cambridge, Cambridge, United
Kingdom). The experiments presented here were carried out with a su-
crose gradient-purified IMV form of VACV or VACV A5L-EGFP.
siRNA knockdown of TRAF2.HeLa cells (4 103 cells in 80l) were
seeded in 96-well plates and incubated for 24 h at 37°C. Before transfec-
tion, media were removed and replaced with DMEM containing 5% FBS
and no antibiotics. TRAF2 small interfering RNA (siRNA) SMARTpool
and four deconvoluted (DC) TRAF2 siRNAs (Dharmacon/Thermo Sci-
entific) were diluted to 0.3M in 1 siRNA buffer (Dharmacon/Thermo
Scientific). The sequences of the DC siRNAswere as follows: TRAF2DC1,
GGAGCAUUGGCCUCAAGGA; TRAF2 DC2, GCAGGUACGGCUACA
AGAU; TRAF2 DC3, CGGUAGAGGGUGAGAAACA; and TRAF2 DC4,
GAAGAAGGCAUUUCUAUUU. Ten microliters of Dharmafect 1 trans-
fection reagent (Dharmacon/Thermo Scientific) diluted in DMEM to a
final concentration of 0.15% was added to the siRNAs and incubated for
20 min. Twenty microliters of this mixture was added to the cells, which
were then incubated for 48 h at 37°C. After this period, media were re-
moved from the plates by inversion and cells were infected with VACV
A5L-EGFP at a multiplicity of infection (MOI) of 0.1 for 1 h at 37°C.
Inocula were removed, and cells were overlaid with DMEM containing
2.5% FBS (2.5% DMEM). At different times p.i., fluorescence levels were
measured using a Synergy HT MultiMode microplate reader (BioTek).
Experiments were carried out in triplicate. Results were analyzed using a t
test.
qPCR confirmation of siRNA knockdown. HeLa cells were seeded
and transfected with TRAF2 siRNA SMARTpool or mock transfected as
described above. After 48 h, samples from 24 wells for each sample were
pooled and total RNA was extracted with the TRIzol reagent (Life Tech-
nologies), according to the manufacturer’s instructions. cDNA was gen-
erated by using either an ImProm system (Promega) or a Pure Link RNA
minikit (Life Technologies) and quantified by quantitative PCR (qPCR)
using SYBR green PCR master mix (Applied Biosystems/Life Technolo-
gies) or a Rotor-Gene SYBR green reverse transcription-PCR kit (Qiagen)
on a Rotor-Gene Q machine (Qiagen). Technical duplicates were per-
formed for all samples. The relative expression of TRAF2 was calculated
using the Pfaffl method (44) and normalized against GAPDH (glyceral-
dehyde-3-phosphate dehydrogenase) (45), hypoxanthine phosphoribo-
syltransferase (HPRT) (46), and beta-glucuronidase (GUSB) (47)
mRNAs using geNorm analysis (48). Data were analyzed using a one-
sample t test in the statistical package GenStat. Primers used for TRAF2
were forward primer 5=-CACCGGTACTGCTCCTTCTG-3= and reverse
primer 5=-TGAACACAGGCAGCACAGTT-3=.
Single-step and multistep growth curves. For single-step (or one-
step) growth curves, TRAF2/ and TRAF2/MEFs were infected with
VACV at anMOI of 10 for 1 h at 37°C. The inoculum was removed (time
point 0 h), and cells were washed with medium and incubated with 2.5%
DMEM. At 0, 4, 8, 12, and 24 h p.i., supernatants were collected and
centrifuged at low speed to remove cell debris. Supernatants were then
incubated with Rb168 antibody (49) (a kind gift from Geoffrey L. Smith,
University of Cambridge, Cambridge, United Kingdom) for 1 h at 37°C in
order to neutralize IMV particles. The titers of the virus present in the
supernatants were determined by plaque assay on BS-C-1 cells. Cells were
scraped intomedium, collected by centrifugation, andpooledwith the cell
debris that had been collected by centrifugation of the supernatant. These
cells were frozen and thawed three times and sonicated, and the titers of
the cell-associated fractions were determined by plaque assay on BS-C-1
cells. For the multistep growth curves, TRAF2/ and TRAF2/MEFs
were infected at an MOI of 0.01 for 1 h at 37°C. Cells were harvested at 0,
4, 8, 12, 24, and 48 h p.i. by scraping them into the medium, frozen and
thawed three times, and sonicated. Virus titers were also determined by
plaque assay on BS-C-1 cells. Themultistep growth curve experiment was
carried out three times, and the single-step growth curve experiment was
carried out twice. Log transformations of the titration data were analyzed
using a repeated-measures mixed model for the multistep growth curve
and the cell-associated and supernatant components of the single-step
growth curve. Eachmodel fitted type time and the type-time interaction as
fixed effects and replicate, replicate-type, replicate-time, and replicate-
type-time as random effects. A different level of variability was assumed at
each time point. The inclusion of random replicate effects and their inter-
actions as random allows the variation in results between replicates to be
taken into account in carrying out statistical tests and in calculating con-
fidence intervals (50).
Virus titration. Serial dilutions of samples were made in 2.5%
DMEM. Dilutions were inoculated in duplicate onto confluent monolay-
ers of BS-C-1 cells in 6-well plates. After infection for 1 h at 37°C, the
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inocula were aspirated, cells were overlaid with 2 ml of 1.5% carboxy
methylcellulose (Sigma) in 2.5% DMEM, and cells were incubated for 2
days at 37°C. The semisolid overlay was aspirated, and cells were washed
briefly with phosphate-buffered saline (PBS) and stained with 0.1% (wt/
vol) crystal violet (Sigma) in 15% ethanol. After rinsing with water, plates
were air dried and the number of plaques was determined.
Measurement of viral plaque size. Semiconfluent monolayers of
TRAF2/ and TRAF2/ MEFs were infected with VACV for 1 h at
37°C. The inoculumwas removed (time point 0 h), cells were washedwith
medium, 2 ml of 1.5% carboxy methylcellulose (Sigma) in 2.5% DMEM
was added, and cells were incubated for 2 days at 37°C. The semisolid
overlay was then aspirated, and cells were washed briefly with PBS and
stained with 0.1% (wt/vol) crystal violet (Sigma) in 15% ethanol. Images
of individual plaques were taken using a Zeiss Axiovert 40 CFL inverted
microscope and a Canon Powershot A640 camera. The diameter of each
plaque was measured using Adobe Photoshop image software.
Protein analysis.TRAF2/ and TRAF2/MEFswere infected with
VACV ormock infected for 1 h at 37°C. After removal of the inocula, cells
were overlaid with 2.5%DMEMandwhole-cell lysates were collected into
lysis buffer (51) at the times indicated below. When required, cells were
pretreated with 50 nM bafilomycin A (Sigma) for 1 h before VACV infec-
tion (52).
Wound healing.Confluentmonolayers of TRAF2/ and TRAF2/
MEFs in a 6-well plate were scored using a 200-l pipette tip to generate
wounds devoid of adherent cells. Monolayers were infected at an MOI of
5 for 1 h on ice with VACVA5L-EGFP and then incubated at 37°C. At the
times indicated below, the monolayers were examined using a Zeiss Ax-
iovert 40 CFL inverted microscope and the number of cells which had
migrated into the wound in each well was counted. Representative images
were captured using a Canon Powershot A640 camera.
Electrophoresis and immunoblotting.Whole-cell extracts were sep-
arated by electrophoresis on 12.5% SDS-polyacrylamide gels and trans-
ferred onto nitrocellulosemembranes. Themembranes were washed with
PBS containing 0.1% Tween 20 and incubated with specific phospho-
SAPK/JNK (Cell Signaling) and SAPK/JNK (Cell Signaling) antibodies.
Immunoreactive bands were visualized using an Immun-Star WesternC
chemiluminescence kit (Bio-Rad). Detection of TRAF2, p84, A46, andD8
was carried out using direct infrared fluorescence (Li-Cor). Blots were
treatedwithOdyssey blocking buffer (Li-Cor) before incubationwithA46
(53), D8 (54), TRAF2 (Santa Cruz), p84 (GeneTex), or -actin (AbCam)
antibodies. Goat anti-rabbit IgG (HL) DyLight 800 conjugate (Cell Sig-
naling) and goat anti-mouse IgG (HL) DyLight 680 conjugate (Cell
Signaling) were used as secondary antibodies. Blots were scanned in an
Odyssey scanner, and bands were quantified usingOdyssey scanning soft-
ware. The Odyssey system uses infrared fluorescent signals, rather than
enzymatic reactions, to detect protein bands on a membrane, making
signal intensity linear within a large dynamic range and enabling accurate
quantification of the amount of protein present (55, 56). A mixed model
was used to analyze the effect of bafilomycinA treatment in the expression
of the early viral protein A46 in TRAF2/ and TRAF2/MEFs follow-
ing VACV infection. In this model, we have fitted line, treatment, time,
and treatment-line, line-time, treatment-time, and line-treatment-time
interactions as fixed effects. The variation between experiments was taken
into account by fitting experiment, treatment-experiment, time-experi-
ment, and time-treatment-experiment as random effects (50).
Flow cytometry. TRAF2/ and TRAF2/MEFs were infected with
VACV A5L-EGFP (MOI 	 10) for 1 h at 4°C. After the inocula were
removed, cells were either processed immediately (0 h p.i.) or incubated at
37°C for 1 h. At 0 h, cells were either scraped into medium or trypsinized
for 10 min at 37°C to remove bound virus. At 1 h p.i., cells were
trypsinized for 10 min at 37°C. Cells were then washed in PBS, fixed in
formalin for 30 min at 4°C, centrifuged at low speed, and resuspended in
500 l of ice-cold PBS. When needed, cells were pretreated with 5 M
JNK inhibitor VIII (JNKi;MerckMillipore) (13) for 1 h prior to infection,
incubated for 1 h p.i., and processed as described above. Mock-infected
samples were included in parallel in every experiment. Samples were an-
alyzed using a BD FACSCalibur flow cytometer and BD CellQuest soft-
ware or the FlowJo software package.
Confocal microscopy. Uncoated VACV cores were labeled and visu-
alized using an anticore rabbit polyclonal serum that recognizes the core
proteins A10, A3, F18, L4, andA4 (57). This serumwas kindly provided by
Geoffrey L. Smith (University of Cambridge, Cambridge, United King-
dom). TRAF2/ and TRAF2/ MEFs were seeded at 105 cells/ml in
round coverslips in a 6-well plate and incubated for 24 h at 37°C. Cells
were infected with VACV (MOI 	 5) for 1 h at 4°C. Inocula were re-
moved, and cells were overlaidwith 2.5%DMEM.At different time points
p.i., the medium was removed, and cells were gently washed three times
with ice-cold PBS and then fixed with PBS containing 4% (wt/vol) para-
formaldehyde for 20min on ice and then for 40min at room temperature
(RT). Cells were then washed again three times with PBS and permeabil-
izedwith PBS containing 2%FBS and 0.1% (wt/vol) saponin (Sigma). The
samples were then incubated for 1 h at RT with mouse monoclonal anti-
body directed against D8 (1:300) and rabbit polyclonal anticore antise-
rum (1:500). After three washes in PBS with 2% FBS, the samples were
incubated for 1 h at RT with Alexa Fluor 488-conjugated antirabbit anti-
body and Alexa Fluor 594-conjugated antimouse antibody (Life Technol-
ogies). After three further washes in PBS, the samples were mounted with
ProLong Gold antifade reagent with DAPI (4=,6-diamidino-2-phenylin-
dole; Molecular Probes). Images were collected using a Zeiss LSM 710
confocal microscope and Zen 2011 software (Zeiss).
RESULTS
TRAF2 has a proviral role in VACV replication. In order to ex-
amine the effect of TRAF2 on VACV replication, we reduced ex-
pression of the protein in HeLa cells using a SMARTpool of four
different siRNAs targeting the mRNA. siRNA transfection was
followed 48 h later by infection at a low multiplicity (MOI	 0.1)
with VACVA5L-EGFP, in which enhanced green fluorescent pro-
tein (EGFP) is fused to the VACV core protein A5 (43), thus cor-
relating fluorescence with VACV multiplication. EGFP fluores-
cence was quantified at 48 h p.i., allowing multiple viral
replication cycles to be completed. These data were compared to
those for mock-transfected cells, cells transfected with a nonspe-
cific siRNA (targeting VP16 from herpes simplex virus type 1),
and a positive-control siRNA which is known to inhibit VACV
replication (targeting PRK-AB1). All wells were examined micro-
scopically for cell death due to potential toxic effects of the siRNA;
none was noted. The two negative controls (mock-transfected
cells and cells transfected with a nonspecific siRNA targeting
VP16) resulted in similar levels of fluorescence, while the siRNA
targeting PRK-AB1 significantly reduced the levels of fluorescence
(Fig. 1A). Knockdown of TRAF2 using the SMARTpool siRNA
reduced fluorescence by approximately 40%, indicating that
TRAF2 has a positive role in VACV replication (Fig. 1A). In this
system, a reduction in fluorescence of 40% is equivalent to a re-
duction of approximately 1 log10 PFU (data not shown).
To rule out potential off-target effects of the siRNAs, the
SMARTpool was deconvoluted; that is, the effects of the four
TRAF2 siRNAs that made up the SMARTpool were tested indi-
vidually. Transfection with three (DC1, DC2, and DC3) of the
four deconvoluted individual siRNAs significantly reduced the
fluorescence to a level similar to that of the SMARTpool (Fig. 1A),
demonstrating the proviral role of TRAF2 in VACV replication.
Transfection of the fourth siRNA (DC4) had no effect on VACV
replication, suggesting that this particular siRNA is nonfunc-
tional.
To assess the effect of the siRNA SMARTpool on TRAF2
Haga et al.
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FIG 1 TRAF2 plays a role in VACV replication. (A) HeLa cells were transfected in triplicate with a TRAF2 siRNA SMARTpool (SP) and four individual
deconvoluted TRAF2 siRNAs (DC1 to DC4). After 48 h, cells were infected with VACV A5L-EGFP at 0.1 PFU/cell, and at 48 h p.i., fluorescence levels were
measured. The experiment was carried out three times in triplicate to produce a data set of three biological replicates each containing three technical replicates,
and the results were analyzed using a t test. P values of
0.05 are noted. (B) HeLa cells were transfected with siRNA targeting VP16, TRAF2 SMARTpool, and
TRAF2DC1,DC2,DC3, andDC4. After 48 h, cells were harvested, RNAwas extracted, and qPCRwas performed to analyze the knockdownof TRAF2 by siRNAs.
TRAF2 expression values in relation to those for the VP16-transfected samples are shown. Error bars indicate the standard errors of the means. P values
(one-sample t test) of
0.05 are noted. (C) Western blot image of protein lysates from HeLa cells mock transfected or transfected with siRNA targeting VP16,
TRAF2 SMARTpool, or TRAF2 DC1, DC2, DC3, or DC4, probed with antibody raised against TRAF2 (top) or -actin (bottom), and visualized using direct
infrared fluorescence (Li-Cor) in an Odyssey scanner. (D)Multistep growth curve. TRAF2/ and TRAF2/MEFs were infected with VACV at 0.01 PFU/cell.
Virus was harvested at the indicated times p.i. Total virus levels were determined by plaque assay on BS-C-1 cells. The graph shows the mean titer of three
biological replicates. Error bars indicate the standard errors of the means. P values of 
0.05 are noted. (E and F) Single-step growth curve. TRAF2/ and
TRAF2/MEFswere infectedwithVACVat 10PFU/cell. At the indicated times p.i., cells (E) and supernatant (F)were collected and virus titerswere determined
by plaque assay onBS-C-1 cells. The graphs show themean titers of two biological replicates. Error bars indicate the standard errors of themeans. (G)The average
diameter of VACV plaques on TRAF2/ (n	 41) and TRAF2/ (n	 39) monolayers. Error bars indicate the standard errors of the means.
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mRNA levels, HeLa cells were transfected with the SMARTpool
targeting TRAF2 and with the deconvoluted siRNAs, and after 48
h, RNA was extracted and the levels of TRAF2 mRNA were deter-
mined by qPCR and normalized to the levels of three housekeep-
ing gene transcripts (GAPDH,HPRT, andGUSB). TRAF2mRNA
was statistically significantly knocked downby SMARTpool, DC1,
DC2, and DC3, but not DC4 (Fig. 1B). In order to verify the effect
of the siRNAs on TRAF2 protein levels, whole-cell lysates were
collected and analyzed by immunoblotting at 48 h posttransfec-
tion. Expression of TRAF2 was reduced following transfection
with TRAF2 SMARTpool and individual siRNAs (Fig. 1C). Thus,
the knockdown of TRAF2 expression by siRNA was evident at
both the mRNA and protein levels. Importantly, the DC4 siRNA
was the least effective at reducing both TRAF2mRNA and protein
levels, correlating with its poor efficacy against virus replication
(Fig. 1A).
To corroborate the siRNA results, we examined the kinetics of
virus replication in MEFs derived from wild-type (WT) and
TRAF2/ mice (42). The TNF--induced NF-B pathway re-
mained functional in TRAF2/ MEFs due to redundancy be-
tween TRAF2 and TRAF5 (58); however, these cells can be used to
investigate the role of TRAF2 in other signaling pathways.
TRAF2/ and TRAF2/ cells were infected with VACV at low
(multistep) and high (single-step) MOIs, samples were harvested
at different times p.i., and virus titers were determined by plaque
assay. The multistep growth curve experiment was carried out
three times, and the single-step growth curve experiment was car-
ried out twice. Data from the replicates were highly reproducible
and in both cases were analyzed for statistical significance using a
mixed model (50) that incorporated data from all replicates.
In themultistep growth curve experiment, VACV replicated to
a significantly lower titer in cells that lackedTRAF2 (P
 0.01 at 24
h and 48 h p.i.; Fig. 1D). At 48 h p.i., the difference was 1.73 log10
PFU. This confirmed our previous results showing that TRAF2 is
important for VACV replication. In a single-step growth curve
experiment, there was no significant difference in viral titers in the
cell-associated fraction (Fig. 1E); however, there was a significant
increase in the amount of EEV present in the supernatant of
TRAF2/ cells at 8, 12, and 24 h p.i. (Fig. 1F). This finding was
unexpected, given the reduction in virus growth in the absence of
TRAF2 under multicycle replication conditions. However, VACV
Western Reserve produces less than 1% of its progeny virions as
EEV (59); therefore, the increase in EEV production in the
TRAF2/ cells is most likely masked in the multistep growth
curve experiment by the overwhelming numbers of IMVs pro-
duced by the infected cells.
Viral plaque size has been shown to correlate with production
of actin tails (discussed in reference 16). To determine whether
TRAF2 influenced this aspect of VACV replication, confluent
monolayers of TRAF2/ and TRAF2/MEFs were infected at a
low MOI (approximately 20 PFU per well) to allow individual
plaques to form over 48 h. The plaques were then visualized with
crystal violet, and the relative diameter was measured. No signif-
icant difference (P 0.05) between VACV plaques on TRAF2/
and TRAF2/MEFs was detected (Fig. 1G).
Overall, these results show that the loss of normal TRAF2 ex-
pression significantly reduces the titer of VACV replication under
multicycle conditions, identifying it as a proviral factor.
Loss of TRAF2 delays the production of early and late VACV
proteins. To identify the stage at which a deficiency of TRAF2
hinders VACV replication, we examined the timing of production
of early and late VACV proteins in TRAF2/ and TRAF2/
MEFs byWestern blotting of cell lysates at various times following
infection at a high multiplicity (MOI 	 10). Equal amounts of
protein were loaded in each well. The presence of equal amounts
was confirmed by blotting with an antibody which recognizes
-actin, which served as a loading control. Expression of a viral
early protein, A46 (53), was first detected at 2 h p.i. in both
TRAF2/ and TRAF2/ cells, but the amount present in the
absence of TRAF2 was markedly reduced (Fig. 2). By 6 h p.i., the
difference in the amount of A46wasmuch less evident. Detectable
expression of a representative late protein, D8 (54), was similarly
delayed in TRAF2/MEFs from 6 to 8 h p.i., but again, it recov-
ered to normal levels by 10 h p.i. (Fig. 2). These results indicate
that loss of TRAF2 delays VACV replication rather than prevents
it, as a consequence of TRAF2 facilitating an early stage of the
VACV life cycle.
TRAF2 is required for VACV-mediated activation of JNK.
VACV infection activates the JNK pathway early in infection (by 3
h p.i.) (13), and TRAF2 is known to activate JNK downstream of
TNFR1 (7). Further, a rise in EEV release from infected cells but
no difference in the amount of cell-associated virus has been de-
scribed in a one-step growth curve experiment of VACV replica-
tion in JNK1/2/ cells (13), findings very similar to our findings
(described above) in TRAF2/ MEFs. We therefore examined
whether VACV-induced phosphorylation of JNK occurs via
TRAF2. TRAF2/ and TRAF2/ MEFs were infected with
VACV, and whole-cell extracts were prepared. Immunoblotting
analysis was carried out for phosphorylated JNK, total JNK, and
p84 as an additional loading control (Fig. 3). This revealed that
while the levels of total JNK were not altered by VACV infection
(Fig. 3, middle), JNK phosphorylation in response to VACV in-
fection was considerably reduced in the absence of TRAF2 (Fig. 3,
top). In TRAF2/ cells, increased JNK phosphorylation was de-
tectable as soon as 0.5 h p.i., with phosphorylation increasing up
FIG 2 Loss of TRAF2 delays the expression of early and late VACV proteins.
TRAF2/ and TRAF2/ MEFs were infected with VACV at 5 PFU/cell or
mock infected for 1 h at 37°C. Unbound virus was removed by washing with
PBS, and cells were incubated with 2.5% DMEM. Whole-cell lysates were
collected at 0, 2, 4, 6, 8, 10, 12, and 24 h p.i. Proteins were separated by
SDS-PAGE and analyzed by immunoblotting with the indicated antibodies,
using direct infrared fluorescence (Li-Cor) in an Odyssey scanner.
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to 6 h p.i. In TRAF2/ cells, phosphorylation was first detected
very faintly at 4 h p.i. and more strongly at 6 and 8 h p.i. This
indicates that TRAF2 is required for early VACV-mediated acti-
vation of JNK, but by 4 h p.i., some TRAF2-independent VACV-
stimulated activation of JNK occurs.
The absence of TRAF2 alters cytoskeletal responses toVACV
infection. While performing the growth curve experiments, we
noticed that the morphology of TRAF2/ and TRAF2/MEFs
varied after VACV infection. In order to compare the CPE caused
by VACV, cells were infected with VACVA5L-EGFP at anMOI of
5 on ice to allow virus to attach to but not enter cells. At 0 h p.i., the
inoculum was removed and the cells were examined. Minimal
CPE was noted in either cell line at this time point (Fig. 4A). The
cultures were then placed at 37°C in 5% CO2 and reexamined at
regular intervals. At 1 h p.i., most TRAF2/ cells (80%) were
still flat, with aminority of cells being shrunken and rounded (Fig.
4A and B). As the infection progressed, the TRAF2/ cells con-
tinued to contract, as expected in VACV-infected cells, with al-
most all cells (90%) being rounded up at 3 h p.i. At 6 h p.i., 24%
of the cells had assumed a flattened, angular morphology, with
some short projections being visible. This sequence of initially
rounding up and then flattening out and producing projections
has been reported previously in a variety of cell types in response
to VACV infection (35, 37). We found that the loss of TRAF2 led
to marked differences in response to VACV infection. Soon after
FIG 3 TRAF2 is required for activation of JNK following VACV infection.
TRAF2/ and TRAF2/ MEFs were infected with VACV at 10 PFU/cell
or mock infected. Whole-cell lysates were collected at the times indicated.
Proteins were separated by SDS-PAGE and analyzed by immunoblotting
with the indicated antibodies. M, mock-infected cells; pJNK, phosphory-
lated JNK.
FIG 4 Altered cytopathic effect in TRAF2/MEFs following VACV infection. (A) TRAF2/ and TRAF2/MEFs were infected with VACV A5L-EGFP at 5
PFU/cell for 1 h at 4°C and then fixed at the indicated times p.i. before being labeledwith Texas Red-phalloidin (red) andDAPI (blue). Images were collectedwith
a Zeiss LSM 710 confocal microscope. (B) Cells with a flat and round morphotype were counted at the indicated times p.i., and the results were analyzed using
a t test. Data are from three independent experiments. P values of
0.05 are noted.
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infection, TRAF2/ MEFs showed rapid and pronounced cell
contractility, with almost all cells (97%) being rounded after only
1 h (Fig. 4A and B). After the initial and rapid contraction of
TRAF2/MEFs, the cells gradually reverted to the angular, flat-
tened morphotype. At 3 h p.i., the changes in the TRAF2/ cells
still proceeded those in the TRAF2/ cells, with significantly
more flat TRAF2/ cells being detected. At 6 h p.i., the influence
of TRAF2 on the cytopathic effect had ceased, with similar num-
bers of flattened and rounded cells being detected in infected
TRAF2/ and TRAF2/MEF monolayers (Fig. 4A and B).
The rounding up of VACV-infected cells is associated with a
loss of adhesion and increase in cell motility (35, 36, 41). Since
rapid rounding up is seen in TRAF2/ MEFs infected with
VACV, we used the in vitro wound healing experiment to deter-
mine whether this was associated with an increase in cell motility.
Confluent monolayers of TRAF2/ and TRAF2/ MEFs were
scratched to create a wound and then infected with VACV at an
MOI of 5 or mock infected. At 1, 3, and 6 h p.i., images of the
wound were taken and the number of cells which had migrated
into the cell-free region was counted (Fig. 5A and B). In unin-
fected cells, a greater number of TRAF2/ cells than TRAF2/
MEFs migrated into the wound, suggesting that cells lacking
TRAF2 have an increased propensity to migrate. This increased
motility was magnified when the cells were infected with VACV,
when by 6 h p.i., 10-fold more VACV-infected TRAF2/ MEFs
thanTRAF2/MEFs hadmigrated into thewound. Thus, overall
these results suggest that TRAF2 acts to dampen down VACV-
induced cytoskeletal rearrangements early postinfection.
The absence of TRAF2 results in reduced numbers of un-
coated viral particles within the cytoplasm. The delay in VACV
protein expression observed in the TRAF2-knockout cells could
be explained by a defect in virus entry. To examine this hypothesis,
FIG 5 Loss of TRAF2 increases VACV-induced cell motility. TRAF2/ and TRAF2/MEFswere scored using a 200-l pipette tip, before beingmock infected
or infected with VACV A5L-EGFP at 5 PFU/cell for 1 h on ice and then incubated at 37°C. (A) The monolayers were examined at the indicated times;
representative images are shown. (B) The number of cells which had migrated into the wound in each well was counted, and the results were analyzed using a t
test. Data are from three independent experiments. *, P
 0.05.
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we employed a virus particle uncoating assay based on confocal
microscopy of cells stained with an antibody directed against the
VACV core, whose epitope is not accessible unless uncoating has
occurred (57). TRAF2/ and TRAF2/MEFs were infected or
mock infected with VACV on ice for 1 h at an MOI of 5 and then
either fixed immediately or fixed after incubation at 37°C for var-
ious periods of time. Samples were then labeled with antibodies
directed against D8, which is present on the IMVmembrane, and
anticore antibody, which detects only uncoated VACV cores and
not IMV or EEV particles (57). This method is regarded as the
most sensitive and specific for studying VACV entry (30). The
entire volume of randomly selected cells (at least 10 per treatment
group) was imaged by capturing serial confocal z-sections. The
z-stacks were then assembled and examined using a three-dimen-
sional (3D) reconstruction view to determine the number of un-
coated cores per cell (Fig. 6A). No D8 or anticore antibody label-
ing was detected in mock-infected controls or in infected cells in
which the primary antibodies were omitted from the procedure
(data not shown). At 0 h p.i., D8 staining (red) was seen on the
surface of infected TRAF2/ andTRAF2/ cells, indicating that
virions had attached, but uncoated cores (green labeling) were
rare. Uncoated cores could be identified at both 30min and 1 h p.i.
in TRAF2/ and TRAF2/ MEFs as punctate green structures
within the cytoplasm. These were counted and compared (Fig.
6B), revealing that there were statistically significantly fewer cores
in TRAF2/MEFs than TRAF2/MEFs and, thus, that TRAF2
promotes VACV entry. In the TRAF2/ MEFs, the majority of
the virions appeared to enter and uncoat within 30 min of infec-
tion, with only a small increase in the number of uncoated cores
per cell being detected at between 30 min and 1 h. In contrast, the
number of uncoated cores in the TRAF2/ MEFs continued to
increase between 30 min and 1 h p.i., suggesting that the loss of
TRAF2 delays, rather than prevents, entry.
The TRAF2-associated delay in VACV entry is not mediated
by the JNK pathway. Slower VACV entry into the TRAF2-knock-
out cells could result from either reduced virus binding to the cell
surface or an alteration in the subsequent entry process. To test
between these possibilities, we analyzed VACV A5-EGFP binding
to TRAF2/ and TRAF2/ MEFs by flow cytometry (29, 60).
Cells were infected (ormock infected) on ice for 1 h, washed three
times with ice-cold PBS, and then either immediately fixed to
examine viral attachment (Fig. 7A) or treated with trypsin to de-
tach surface-bound virions before being fixed (Fig. 7B and C). In
all cases, only background levels of fluorescence were seen from
mock-infected cells, while, as expected, substantial signals were
obtained in the presence of fluorescently labeled virus. When the
FIG 6 VACV entry is delayed in MEFs lacking TRAF2. (A) TRAF2/MEFs (top) and TRAF2/MEFs (bottom) were mock infected or infected with VACV
at 10 PFU/cell for 1 h at 4°C. The cells were then fixed after 0 h, 0.5 h, or 1 h of incubation at 37°C. Mock-infected cells were incubated for 1 h. Cells were then
labeled with anticore antibody, which labels uncoated virus cores (green), or anti-D8 antibody (red) and the nuclear stain DAPI (blue). z-stack images of at least
10 randomly selected cells per treatment group were collected and assembled using 3D reconstruction software (Zen Black, 2011), and the number of green core
particles per cell was counted. A representative image of each sample is shown (3D reconstruction, maximum-intensity projection mode). (B) The average
number of uncoated cores in TRAF2/ and TRAF2/MEFs at the times indicated. Error bars represent standard errors of the means. Results were analyzed
using a t test. P values of
0.05 are shown.
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samples were examined at 0 h p.i., cell-associated fluorescence in
the absence of trypsin treatmentwas very similar in the TRAF2/
andTRAF2/ cells (Fig. 7A) andwas similarly reduced by trypsin
treatment, as seen by the shift in the fluorescence curves of both
the TRAF2/ and TRAF2/ infected cells to the left in Fig. 7B.
Thus, the presence or absence of TRAF2 did not affect attachment
of virions to the surface of the cell. However, if the cells were
incubated at 37°C for 1 h to allow entry to proceed prior to treat-
ment with trypsin and fixation, the majority of the viral fluores-
cencewas trypsin resistant in the TRAF2/ cells, but a substantial
proportion of the signalwas still trypsin sensitive in theTRAF2/
cells (Fig. 7C). The fluorescence profiles of mock-infected cells
were used to differentiate between infected and uninfected cells,
and the results were quantified (Fig. 7D). At 1 h p.i., significantly
more TRAF2/MEFs than TRAF2/MEFs contained internal-
ized virions. Thus, TRAF2 has a role in facilitating VACV entry
into MEFs but does not affect virus attachment.
To test if the decreased ability of VACV to activate the JNK
signaling pathway in the absence of TRAF2 was involved in the
entry defect, we used a JNK inhibitor (JNKi [13]) to see if this
would reproduce the effect of the loss of TRAF2 in MEFs. How-
ever, pretreatment of TRAF2/MEFs (orTRAF2/MEFs)with
JNKi did not reduce virus entry (Fig. 7C and D), indicating that
TRAF2 influences VACV entry in a JNK-independent manner.
TRAF2 may act in the plasma membrane-associated entry
pathway.VACV enters cells via one of two pathways, either fusion
at the plasmamembrane or endocytosis. To test which entry path-
way is dependent on TRAF2, we treated cells with bafilomycin
A, which blocks acidification of endosomes and thus prevents
VACV entry by endocytosis (52). We pretreated TRAF2/ and
TRAF2/ MEFs with bafilomycin A, infected the cells with
VACV, and used early gene (A46) expression as a measure of viral
entry. Similar to our previous results (Fig. 2), we found consider-
ably less A46 protein (an approximately 50% reduction) in
TRAF2/MEFs than in TRAF2/MEFs at 2 h p.i. (Fig. 8A). As
expected, bafilomycin A treatment significantly reduced the ex-
FIG 7 Delayed VACV entry in MEFs is JNK independent. (A) TRAF2/ and TRAF2/MEFs were infected with VACV A5L-EGFP at 10 PFU/cell for 1 h at
4°C. Cells were scraped intomedium at 0 h p.i. and fixed, and fluorescence was quantified by flow cytometry. (B) TRAF2/ and TRAF2/MEFs were infected
with VACV A5L-EGFP at 10 PFU/cell for 1 h at 4°C. Cells were trypsinized for 10 min at 0 h p.i., fixed, and processed as described above. (C) TRAF2/ and
TRAF2/ MEFs were infected with VACV A5L-EGFP at 10 PFU/cell for 1 h at 4°C. Cells were collected at 1 h p.i., trypsinized for 10 min, and processed as
described above. Additional samples were pretreated with 5 M JNKi for 1 h prior to infection, incubated for 1 h p.i., and then processed. (D) The average
number of infected cells at 1 h p.i. calculated from flow cytometry data from five independent experiments. Error bars represent standard errors of the means. P
values of
0.05 (t test) are shown.
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pression of A46 in both TRAF2/ (P 	 0.036) and TRAF2/
(P 	 0.019) cells. In TRAF2/ MEFs, bafilomycin A treatment
reduced the amount of A46 present at 2 h p.i. by 31% compared to
the amount present in untreated TRAF2/ MEFs (Fig. 8A and
B). This finding is similar to previous reports (30, 61) and consis-
tent with the loss of the endosomal pathway and the increased
dependence of the virus on plasmamembrane fusion for entry. In
comparison, bafilomycin A treatment of TRAF2/ MEFs had a
much greater effect on virus entry, consistently reducing A46 ex-
pression by an average of 67% in treated versus untreated
TRAF2/ MEFs at 2 h p.i. (Fig. 8A and B). These results reveal
that VACV relies on the endosomal pathway to a greater extent in
the absence of TRAF2 and therefore suggest that TRAF2 may fa-
cilitate entry of VACV via plasma membrane fusion rather than
endocytosis.
DISCUSSION
TRAF2 is a member of the TNF receptor-associated factor family.
It is recruited to TNFR1 to effect activation of the canonical
NF-B pathway (62), the JNK pathway (63), and the p38 pathway
(64), as well as inhibition of apoptosis (4). Less well defined roles
for TRAF2 in the regulation of autophagy (65) and the epidermal
growth factor receptor pathway (66) have been reported. VACV is
known to modulate some of these TRAF2-regulated pathways;
therefore, we investigated the role of TRAF2 in VACV replication.
We found that siRNA knockdown of TRAF2 in HeLa cells hin-
dered the replication of VACV (Fig. 1A). This result was con-
firmed in a multistep growth curve experiment in TRAF2/
MEFs (Fig. 1D). This VACVgrowth defect was not apparent in the
cell-associated fraction of a one-step growth curve in TRAF2/
MEFs (Fig. 1E), indicating that the defectwas not severe enough to
be distinguished by plaque assay in a single replication cycle but
required multiple rounds of replication to magnify the effect be-
fore it could be detected.
While no difference in the cell-associated fraction of the one-
step growth curve was detected, the supernatant of infected
TRAF2/MEFs unexpectedly showed greater numbers of EEVs.
Increased EEV production is an unusual finding which has previ-
ously been reported in viruses with a deleted or mutated A34R
gene, such as VACV strain IHD-J (59, 67–69), or in cells lacking
JNK1/2 (13). As TRAF2 has previously been reported to be in-
volved in JNK activation, we examined the role of TRAF2 in
VACV-induced phosphorylation of JNK. TRAF2 was indeed
found to be required for rapid JNK pathway activation, substan-
tiating the previous report describing a correlation between
VACV-induced JNK activation and EEV release (13). Moreover,
our findings identify the activation of the JNK pathway by VACV
to be at the level of the adaptor complex or higher since TRAF2 is
a crucial component of the initial stages of activation of the JNK
pathway. Themechanism by which JNK activation promotes EEV
release is unknown but has been suggested to be linked to altered
microtubule and actin organization in the absence of JNK activa-
tion, promoting transport of cell-associated enveloped virus
(CEV) to the cell surface and release of EEV (13).
As described above, the increase in EEV production identified
in a one-step growth curve did not translate into an increase in
viral replication in a multistep growth curve. This may be because
less than 1% of VACV Western Reserve virions form EEVs (59),
and their impact is therefore easily masked by overwhelming
numbers of IMVs. Alternative explanations for the phenomenon
are that increased numbers of EEVs produced from TRAF2/
cells are unable to reinfect TRAF2/ cells efficiently or that loss of
TRAF2 results in a reduction in the production of CEVs. We in-
vestigated both of these scenarios and found that EEVs produced
from TRAF2/ cells infected TRAF2/ and TRAF2/ cells
equally well and that after 8 h of infection with VACV similar
numbers of CEVs were present on the surface of TRAF2/ and
TRAF2/ cells (data not shown). The effect of an increase in EEV
production on the spread of VACV through a cell monolayer has
not previously been investigated in detail; however, work with the
mutant strain IHD-J suggested that increasing EEV levels have
only a minor effect on overall spread through a monolayer (67),
supporting the results from the TRAF2/MEFs presented here.
As we detected an overall reduction in VACV replication in a
multicycle growth curve in cells lacking TRAF2, we suspected that
TRAF2 played an additional role, other than JNK activation, in the
VACV life cycle and that this rolewas proviral. In order to uncover
this proviral role of TRAF2 in VACV replication, we examined
viral protein expression during a single-step growth curve exper-
iment comparing TRAF2/ and TRAF2/MEFs. This revealed
that despite no overall difference in viral growth in the cell-asso-
ciated fraction, there was a delay in both early and late protein
expression (Fig. 2), indicating a role for TRAF2 during early stages
of viral replication. We measured virus entry using uncoating ex-
FIG 8 VACV entry in TRAF2/ cells is markedly reduced by bafilomycin A treatment. (A) TRAF2/ and TRAF2/MEFs were infected with VACV at 1 to
10 PFU/cell for 1 h at 37°C. Some cells were pretreatedwith 50 nMbafilomycinA (Bfl) for 1 h before infection, with subsequent virus infection and overlay carried
out in the presence of the chemical. Whole-cell lysates were collected at the indicated times p.i. Proteins were separated by SDS-PAGE and analyzed by
immunoblottingwith the indicated antibodies. (B) Proteins were quantified and normalized against the amount of-actin usingOdyssey scanning software. The
data represented are the averages and standard errors of the means (error bars) from four biological replicates. Using mixed-model analysis, bafilomycin A
treatment significantly influenced the expression of A46 in both TRAF2/ cells (P	 0.036) and TRAF2/ cells (P	 0.019).
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periments (Fig. 6) and cell fluorescence (Fig. 7) and found that
TRAF2 promotes VACV entry. Treatment of cells with a JNK in-
hibitor did not influence VACV entry (Fig. 7C), indicating that
TRAF2 facilitates VACV entry independently of its role in the JNK
activation pathway. Loss of TRAF2 did not result in an absolute
failure of virus entry, since uncoated virions were still seen within
TRAF2/ cells (Fig. 6A) and viral protein expressionwas delayed
rather than prevented (Fig. 2 and 8). One explanation for the
slower viral entry was that loss of TRAF2 impacted only one of the
two main routes of VACV entry, either plasma membrane fusion
or endocytosis. Bafilomycin A treatment was used to inhibit the
endosomal pathway, and while this produced only a moderate
reduction in virus entry in TRAF2/ cells, a much greater reduc-
tion was seen in TRAF2/MEFs, revealing the overdependence
of VACV on the endosomal route of entry in the absence of
TRAF2 (Fig. 8A and B). This implies that the plasma membrane
route of entry is not functioning normally in cells lacking TRAF2
and suggests that TRAF2 may assist VACV entry specifically via
plasma membrane fusion. This hypothesis is attractive, since the
endosomal pathway of VACV entry has been suggested to be
slower than the plasma membrane pathway of entry (30), which
would explain why the TRAF2/ defect results in a delay, rather
than a block, in virus entry and, thus, why multiple rounds of
replication are required for detection of the defect. This model is
outlined in Fig. 9. The identification of a protein involved in
plasma membrane entry would be noteworthy, since most re-
cently identified cellular proteins with an influence on VACV en-
try have been shown to influence the endocytic pathway, such as
VPEF (70), integrin1 (71), and CD98 (72).Whether TRAF2 acts
directly on the virion at the plasma membrane level or influences
a specific pathway utilized by the virus during plasma membrane
fusion remains to be established.
Our studies of the TRAF2/ MEFs also revealed a role for
TRAF2 in the VACV-induced CPE. The initial cytoskeletal
changes induced by VACV in the TRAF2/ MEFs were more
rapid and extensive than those identified in theWTMEFs (Fig. 4),
and cellmotility was enhanced (Fig. 5), indicating that TRAF2 acts
to curb the early CPE and cell motility induced by VACV infec-
tion. Changes to cell shape and motility in response to VACV
infection depend on early viral gene expression (36). However,
TRAF2-knockout cells display delayed virus entry and early gene
expression butmore rapid changes to cell shape andmotility. This
apparent contradiction may be due to the delayed early gene ex-
pression still being sufficient to trigger cytoskeletal alterations.
The cytoskeletal changes induced by VACV are biologically im-
portant because they resemble those found in tumors and wound
healing (36). Themechanisms bywhichVACV alters the cytoskel-
eton remain to be fully characterized, but the viral protein F11
plays a central role. F11 acts as a dominant negative protein in the
RhoA-mDia pathway, preventing RhoA from interacting with
ROCK and therefore suppressing pathway signaling. Early cell
contraction, detachment, and motility are F11-dependent phe-
nomena (39–41), and the protein is also involved in late projec-
tion formation and EEV release (39, 40, 73). F11 restores motility
and induces a cytopathic effect in modified vaccinia virus Ankara
and myxoma virus, both of which lack a functional F11 (38, 40,
74). One explanation of the exaggerated CPE observed in infected
TRAF2/MEFs is that TRAF2 is involved in RhoA stimulation.
The absence of TRAF2 could lead to reduced RhoA stimulation,
potentiating the effect of F11 and leading to more rapid and ex-
tensive cytoskeletal changes. However, while TNF- activation
has been linked toCdc42, Rac, andRhoA activation (75–80), there
is no evidence connecting TRAF2 to these pathways. In fact, two
studies have shown that TRAF2 is not required for TNF--
associated cytoskeletal manipulation (75, 79). An alternative ex-
planation for the cytoskeletal changes seen in VACV-infected
TRAF2/ MEFs is a lack of JNK1/2 phosphorylation. The JNK
pathway is known to influence the VACV CPE at 3 and 6 h p.i.
(13), and stimulation of the JNKpathway by the compound trans-
2-hexadecenal results in cytoskeletal changes similar to those de-
scribed in TRAF2/MEFs infected with VACV (81). It would be
interesting to compare theCPE seen inTRAF2/ and JNK1/2/
MEFs at 1 h after infectionwith VACV to see if similar changes are
noted. However, comparison of results from cell motility experi-
FIG 9 Proposedmodel for the role of TRAF2 in VACV entry. In normal cells, virus entry proceeds via either of two routes, direct entry at the plasmamembrane
or following endocytosis, with the former route forming the relatively fast route. In the absence of TRAF2, entry at the plasma membrane is inhibited and
infection occurs predominantly via the relatively slow endocytic route. The absence of TRAF2 also inhibits early activation of JNK, but this is not relevant to virus
entry.
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ments in VACV-infected TRAF2/MEFs (this work) and JNK1/
2/MEFs (13) reveals opposing effects, with the loss of JNK1/2
reducing cell motility but the loss of TRAF2 enhancing motility,
suggesting that the situation is not straightforward. The role of
TRAF2 in regulating cytoskeletal responses, such as cell shape and
motility, in the face of a VACV infection likely involves more
pathways than the JNK pathway alone.
We have found that TRAF2 affects the VACV life cycle in three
distinct manners: activating the JNK pathway, influencing cyto-
skeletal rearrangement, and promoting virus entry. The exact re-
lationship between these three functions remains to be defined. To
the best of our knowledge, this is the first report of TRAF2 being
involved in virus entry. Further investigations into themechanism
of action of TRAF2 in VACV replication may shed new light on
the function of this protein and provide novel regulatory tools for
key cellular pathways.
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